Bernstein raised the firm’s price target on Johnson & Johnson to $159 from $158 and keeps a Market Perform rating on the shares following a solid beat in Q1. The firm maintained FY25 EPS guidance, as dilution from the Intra-Cellular acquisition and from tariffs was largely offset by FX favorability.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Hold Rating for Johnson & Johnson Amid Mixed Outlook and Macroeconomic Challenges
- Johnson & Johnson: Balancing Stability and Risks Amid Tariff Challenges
- Cautious Outlook on Johnson & Johnson’s Orthopedic Segment Amid Slowed Growth and Competitive Pressure
- Johnson & Johnson Stock: Fairly Valued with Neutral Outlook Amid Uncertain Growth Prospects
- Johnson & Johnson’s Promising Outlook: Strong Q1 2025 Performance and Strategic Growth Initiatives Justify Buy Rating